Objective: To investigate the effects of Atorvastatin Combined with tegrilol on inflammatory factors, blood lipids and adverse cardiac events in patients with unstable angina pectoris (UAP). Methods: 103 patients with coronary heart disease and UAP who were admitted to our hospital from February 2016 to February 2019 were selected, they were randomly divided into study group (n=52), control group (n=51). The control group was treated with Atorvastatin Combined with clopidogrel, and the study group was treated with Atorvastatin Combined with clopidogrel. The clinical efficacy, inflammatory factors, blood lipids, angina pectoris and adverse cardiac events were compared between the two groups. Results: The clinical efficacy of the study group was 88.46% (46/52) after one month of treatment, which was higher than 66.67% (34/51) of the control group (P<0.05). One month after treatment, total cholesterol (TC), hypersensitive C-reactive protein (hs-CRP), triglyceride (TG), interleukin-6 (IL-6), low density lipoprotein cholesterol (LDL-C), frequency of angina attack, tumor necrosis factor-α (TNF-α) and duration of angina pectoris in both groups decreased, while high density lipoprotein cholesterol (HDL-C) decreased. The TC, TG, LDL-C, IL-6, hs-CRP, TNF-α, angina attack times and duration of angina in the study group were lower than those in the control group one month after treatment, while HDL-C was higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse cardiac events between the two groups (P>0.05). Conclusion: Atorvastatin combined with Tiglillo is effective in the treatment of UAP patients with coronary heart disease. It can effectively improve the levels of inflammatory factors and blood lipids without increasing the incidence of adverse cardiac events, and has high clinical value. [ABSTRACT FROM AUTHOR]